Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
96.77
+4.68 (5.08%)
Mar 9, 2026, 3:43 PM EDT - Market open
Protagonist Therapeutics Employees
Protagonist Therapeutics had 132 employees as of December 31, 2025. The number of employees increased by 6 or 4.76% compared to the previous year.
Employees
132
Change (1Y)
6
Growth (1Y)
4.76%
Revenue / Employee
$348,606
Profits / Employee
-$985,977
Market Cap
6.17B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| CRISPR Therapeutics AG | 393 |
| Mirum Pharmaceuticals | 372 |
| Immunovant | 362 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 238 |
PTGX News
- 7 days ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 11 days ago - CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 11 days ago - Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 13 days ago - Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - Accesswire
- 2 months ago - Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - Accesswire
- 2 months ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 3 months ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 4 months ago - Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire